Table2:
Multivariable Logistic Regression Analysis Assessing Relationship between clinic-demographic variables and patient-reported moderate to severe xerostomia
| Variables | Univariate OR | (95% CI) | Univariate P | Multivariable OR | (95% CI) | Multivariable P | BFDP |
|---|---|---|---|---|---|---|---|
| Age at diagnosis, y | 1.00 | (0.99–1.02) | 0.563 | 1.00 | (0.99–1.02) | 0.605 | 0.999 |
| Survival time, y | 0.99 | (0.95–1.02) | 0.517 | 0.98 | (0.92–1.05) | 0.584 | 0.997 |
| Radiation Dose, Gy | 1.04 | (0.98–1.10) | 0.169 | 0.99 | (0.92–1.06) | 0.711 | 0.998 |
| Sex | 0.006 | ||||||
| Male | Ref | Ref | |||||
| Female | 1.69 | (1.16–2.45) | 0.006 | 1.82 | (1.22–2.71) | 0.003 | 0.568 |
| Education new | 0.004 | ||||||
| >Highschool | Ref | Ref | |||||
| ≤Highschool | 1.73 | (1.22–2.45) | 0.002 | 1.73 | (1.19–2.52) | 0.004 | 0.636 |
| Race/Ethnicity | |||||||
| Non-Hispanic white | Ref | Ref | |||||
| Non-Hispanic black | 0.93 | (0.34–2.59) | 0.893 | 0.74 | (0.24–2.24) | 0.594 | 0.968 |
| Hispanics | 0.78 | (0.37–1.62) | 0.502 | 0.72 | (0.34–1.56) | 0.410 | 0.971 |
| Other | 2.07 | (0.46–9.32) | 0.343 | 1.98 | (0.41–9.54) | 0.394 | 0.958 |
| Subsite | 0.760 | ||||||
| Tonsil | Ref | Ref | |||||
| Base of tongue + GPS | 1.11 | (0.84–1.46) | 0.460 | 1.02 | (0.74–1.4) | 0.901 | 0.990 |
| Others | 1.04 | (0.49–2.20) | 0.923 | 0.87 | (0.39–1.92) | 0.724 | 0.976 |
| T classification | 0.175 | ||||||
| 1 | Ref | Ref | |||||
| 2 | 1.08 | (0.79–1.48) | 0.632 | 1.01 | (0.69–1.46) | 0.973 | 0.988 |
| 3 | 1.14 | (0.75–1.73) | 0.548 | 0.87 | (0.51–1.47) | 0.594 | 0.982 |
| 4 | 1.73 | (1.06–2.80 | 0.027 | 1.32 | (0.72–2.43) | 0.374 | 0.974 |
| N classification | 0.191 | ||||||
| N0 | Ref | Ref | |||||
| N1+2a | 1.02 | (0.60–1.74) | 0.930 | 1.10 | (0.61–1.98) | 0.752 | 0.981 |
| 2b+3 | 1.09 | (0.66–1.79) | 0.741 | 1.07 | (0.60–1.88) | 0.825 | 0.982 |
| 2c | 1.57 | (0.90–2.76) | 0.115 | 1.33 | (0.71–2.5) | 0.380 | 0.974 |
| HPV status | 0.546 | ||||||
| Negative | Ref | Ref | |||||
| Positive | 0.90 | (0.51–1.59) | 0.722 | 1.17 | (0.62–2.18) | 0.630 | 0.979 |
| Unknown | 0.79 | (0.45–1.39) | 0.416 | 0.96 | (0.51–1.83) | 0.905 | 0.981 |
| Cigarettes Smoking | |||||||
| Never | Ref | Ref | |||||
| Former smokers at time of diagnosis | 0.93 | (0.69–1.25) | 0.632 | 0.91 | (0.66–1.25) | 0.565 | 0.988 |
| Quit smoking subsequent to diagnosis | 1.20 | (0.76–1.92) | 0.435 | 1.05 | (0.63–1.73) | 0.856 | 0.984 |
| Current smoker | 2.96 | (1.43–6.15) | 0.004 | 2.56 | (1.19–5.47) | 0.016 | 0.800 |
| Don’t know | 1.15 | (0.36–3.70) | 0.810 | 1.19 | (0.36–3.98) | 0.772 | 0.969 |
| Solid Food pre-Tx | 0.667 | ||||||
| No | 0.77 | (0.23–2.54) | 0.665 | Ref | |||
| Yes | Ref | 0.95 | (0.25–3.54) | 0.940 | 0.968 | ||
| Treatment Group | 0.133 | ||||||
| Single Modality | Ref | Ref | |||||
| Multimodality | 1.25 | (0.93–1.69) | 0.135 | 0.80 | (0.12–5.58) | 0.824 | 0.961 |
| Chemotherapy | 0.102 | ||||||
| No | Ref | Ref | |||||
| Yes | 1.28 | (0.95–1.72) | 0.103 | 1.22 | (0.18–8.23) | 0.838 | 0.961 |
| Surgery | 0.098 | ||||||
| No 0 | Ref | Ref | |||||
| Yes – Robotic | 0.31 | (0.09–1.07) | 0.063 | 0.49 | (0.10–2.31) | 0.368 | 0.957 |
| Yes – Open | 1.53 | (0.31–7.63) | 0.603 | 3.01 | (0.42–21.42) | 0.272 | 0.951 |
| Neck Dissection | 0.393 | ||||||
| No | Ref | Ref | |||||
| Yes | 0.81 | (0.59–1.12) | 0.200 | 0.86 | (0.6–1.22) | 0.395 | 0.985 |
| RT Schedule | 0.493 | ||||||
| Standard Fractionation | Ref | Ref | |||||
| Accelerated | 1.16 | (0.76–1.79) | 0.492 | 0.99 | (0.55–1.79) | 0.983 | 0.982 |
| RT Type | 0.001 | ||||||
| 3D-CRT | Ref | Ref | |||||
| IMRT-Bilateral (SF+WF+VMAT) + Proton | 0.45 | (0.25–0.82) | 0.008 | 0.35 | (0.16–0.73) | 0.006 | 0.641 |
| Ipsilateral IMRT | 0.26 | (0.13–0.55) | < 0.001 | 0.19 | (0.07–0.47) | <0.001 | 0.223 |
| Xerostomia During RT | 0.226 | ||||||
| No | Ref | Ref | |||||
| Yes | 0.96 | (0.71–1.29) | 0.777 | 0.99 | (0.72–1.36) | 0.937 | 0.990 |
Abbreviations: T, tumor; RT, radiotherapy; 3D-CRT; three-dimensional conformal radiotherapy; IMRT-SF, Intensity modulated radiotherapy split-field technique; IMRT-WF, Intensity modulated radiotherapy whole-field technique; VMAT, Volumetric-modulated arc therapy; BFDP, Bayesian false-discovery probabilities.
Statistical significance P ≤ 0.05.
BFDP ≤ 0.8 noteworthy associations.